National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma

doi:10.3748/wjg.v30.i9.1018

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2615)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

HTML

2224

Figures (1-2)

Tables (1-4)

Sum=2378

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=110

Mar 7, 2024 (publication date) through May 13, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines

World J Gastroenterol. Mar 7, 2024; 30(9): 1018-1042
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1018

Table 4 Clinical trials of adjuvant treatment in hilar cholangiocarcinoma

Study	Design	Sample size	Treatment	Control	Key findings
JCOG1202, ASCOT	Phase 3	Total: 440; CCA: 180	S-1¹	Observation	3-yr OS: 77.1% vs 67.6% (95%CI: 61.0%-73.3%); 3-yr RFS: 62.4% vs 50.9% (95%CI: 44.1%-57.2%)
BILCAP	Phase 3	Total: 447; CCA: 284	Capecitabine, duration: 6 months	Observation	OS (month): 51.1 vs 36.4 (95%CI: 34.6%-59.1%); RFS (month): 24.4 vs 17.5 (95%CI: 18.6%-35.9%)
SWOG S0809	Phase 2	Total: 79; CCA: 53	gemcitabine and capecitabine followed by CRRT	None	Median OS: 35 months (R0, 34 months, R1, 35 months)

¹S-1 is available only in Japan.

95%CI: 95% Confidence interval; CCA: Cholangiocarcinoma; CRRT: Concomitant chemoradiation therapy; OS: Overall survival; RFS: Recurrence-free survival.

Citation: Dar FS, Abbas Z, Ahmed I, Atique M, Aujla UI, Azeemuddin M, Aziz Z, Bhatti ABH, Bangash TA, Butt AS, Butt OT, Dogar AW, Farooqi JI, Hanif F, Haider J, Haider S, Hassan SM, Jabbar AA, Khan AN, Khan MS, Khan MY, Latif A, Luck NH, Malik AK, Rashid K, Rashid S, Salih M, Saeed A, Salamat A, Tayyab GUN, Yusuf A, Zia HH, Naveed A. National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma. World J Gastroenterol 2024; 30(9): 1018-1042
URL: https://www.wjgnet.com/1007-9327/full/v30/i9/1018.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i9.1018